Rezaul Karim, PhD

Interest: Biologics drug development, (cancer) immunotherapies.

Dr. Karim has been involved in a number of antibody-based therapeutics discovery and development programs that are currently in clinical development. He completed Bachelor of Science (Honors) and Master of Science from the Department of Microbiology, University of Dhaka. He then moved to the Netherlands and completed his Master of Science in Immunology at the University of Utrecht where he joined the laboratory of Prof. Dr. Hans Clevers (Hubrecht Institute) studying Wnt signaling in colorectal cancer. He completed his PhD in cancer immunology at the University of Leiden (Prof. Dr. Cornelis Melief) followed by a postdoctoral fellowship in cancer (immuno)biology and metastasis in Vienna (Prof. Dr. Josef Penninger). Afterwards, he worked in a NASDAQ-listed biotech company focusing on preclinical development of bispecific antibody-mediated cancer immunotherapies. Later, he was involved in development of biologics at WHO-Utrecht University Center of Excellence for Affordable Biotherapeutics. His current work involves largely in CMC and nonclinical development of biologics, biosimilars and vaccines.